a The D-Lab: Decision Support for Precision Medicine, GROW - School for Oncology and Developmental Biology , Maastricht University Medical Centre+ , Maastricht , the Netherlands.
b Department of Radiation Oncology (MAASTRO), GROW - School for Oncology and Developmental Biology , Maastricht University Medical Center+ , Maastricht , the Netherlands.
Acta Oncol. 2018 Nov;57(11):1499-1505. doi: 10.1080/0284186X.2018.1484156. Epub 2018 Jun 28.
Previous studies revealed that dose escalated radiotherapy for prostate cancer patients leads to higher tumor control probabilities (TCP) but also to higher rectal toxicities. An isotoxic model was developed to maximize the given dose while controlling the toxicity level. This was applied to analyze the effect of an implantable rectum spacer (IRS) and extended with a genetic test of normal tissue radio-sensitivity. A virtual IRS (V-IRS) was tested using this method. We hypothesized that the patients with increased risk of toxicity would benefit more from an IRS.
Sixteen localized prostate cancer patients implanted with an IRS were included in the study. Treatment planning was performed on computed tomography (CT) images before and after the placement of the IRS and with a V-IRS. The normal tissue complication probability (NTCP) was calculated using a QUANTEC reviewed model for Grade > =2 late rectal bleeding and the number of fractions of the plans were adjusted until the NTCP value was under 5%. The resulting treatment plans were used to calculate the TCP before and after placement of an IRS. This was extended by adding the effect of two published genetic single nucleotide polymorphisms (SNP's) for late rectal bleeding.
The median TCP resulting from the optimized plans in patients before the IRS was 75.1% [32.6-90.5%]. With IRS, the median TCP is significantly higher: 98.9% [80.8-99.9%] (p < .01). The difference in TCP between the V-IRS and the real IRS was 1.8% [0.0-18.0%]. Placing an IRS in the patients with SNP's improved the TCP from 49.0% [16.1-80.8%] and 48.9% [16.0-72.8%] to 96.3% [67.0-99.5%] and 90.1% [49.0-99.5%] (p < .01) respectively for either SNP.
This study was a proof-of-concept for an isotoxic model with genetic biomarkers with a V-IRS as a multifactorial decision support system for the decision of a placement of an IRS.
先前的研究表明,前列腺癌患者的剂量递增放疗可提高肿瘤控制概率(TCP),但也会增加直肠毒性。开发了一种等毒模型,以在控制毒性水平的同时最大化给定剂量。将该模型应用于分析植入式直肠间隔物(IRS)的效果,并通过正常组织放射敏感性的遗传测试进行扩展。使用这种方法测试了虚拟 IRS(V-IRS)。我们假设毒性风险增加的患者将从 IRS 中受益更多。
本研究纳入了 16 名接受 IRS 植入的局限性前列腺癌患者。在 IRS 放置前后和使用 V-IRS 时,在计算机断层扫描(CT)图像上进行治疗计划。使用经过 QUANTEC 审查的模型计算 2 级以上晚期直肠出血的正常组织并发症概率(NTCP),并调整计划的分数数量,直到 NTCP 值低于 5%。使用所得治疗计划计算 IRS 放置前后的 TCP。通过添加两个已发表的用于晚期直肠出血的遗传单核苷酸多态性(SNP)的效果,对其进行了扩展。
IRS 前患者优化计划的中位 TCP 为 75.1%[32.6-90.5%]。使用 IRS 时,中位 TCP 显著更高:98.9%[80.8-99.9%](p<.01)。V-IRS 和真实 IRS 之间的 TCP 差异为 1.8%[0.0-18.0%]。在携带 SNP 的患者中放置 IRS 可将 TCP 从 49.0%[16.1-80.8%]和 48.9%[16.0-72.8%]提高至 96.3%[67.0-99.5%]和 90.1%[49.0-99.5%](分别为 p<.01)用于任一 SNP。
本研究是使用 V-IRS 作为多因素决策支持系统对 IRS 放置决策进行遗传生物标志物等毒性模型的概念验证。